Francisco Javier Sánchez-Martín
YOU?
Author Swipe
View article: Data from HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
Data from HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer Open
Despite the clinical benefit of trastuzumab, eventually all HER2-amplified gastric cancer tumors develop drug resistance. We aimed to identify molecular mechanisms of acquired resistance to trastuzumab in gastric cancer by using well-estab…
View article: Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer Open
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
View article: Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer Open
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
View article: Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer Open
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
View article: Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer Open
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
View article: Supplementary Data from HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
Supplementary Data from HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer Open
Supplementary Figures and Material and Methods
View article: Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer Open
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
View article: Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer Open
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
View article: Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer Open
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
View article: Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer Open
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
View article: Data from HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
Data from HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer Open
Despite the clinical benefit of trastuzumab, eventually all HER2-amplified gastric cancer tumors develop drug resistance. We aimed to identify molecular mechanisms of acquired resistance to trastuzumab in gastric cancer by using well-estab…
View article: Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer Open
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
View article: Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer Open
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
View article: Data from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Data from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer Open
In patients with trastuzumab-resistant HER2-positive breast cancer, the combination of everolimus (mTORC1 inhibitor) with trastuzumab failed to show a clinically significant benefit. However, the combination of mTOR inhibition and the anti…
View article: Supplementary Data from HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
Supplementary Data from HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer Open
Supplementary Figures and Material and Methods
View article: Data from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Data from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer Open
In patients with trastuzumab-resistant HER2-positive breast cancer, the combination of everolimus (mTORC1 inhibitor) with trastuzumab failed to show a clinically significant benefit. However, the combination of mTOR inhibition and the anti…
View article: Data from The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Data from The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer Open
Purpose: Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic colorectal cancer (MCRC). However, patients ultimately develop disease progression, often driven by ac…
View article: Data from The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Data from The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer Open
Purpose: Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic colorectal cancer (MCRC). However, patients ultimately develop disease progression, often driven by ac…
View article: Supplementary Material from The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Supplementary Material from The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer Open
Figure S1: EGFR mutants binding to CTX, Sym004, PNM Figure S2: Clonogenic assay in EGFR mutants with CTX, Sym004, PNM
View article: Supplementary Material from The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Supplementary Material from The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer Open
Figure S1: EGFR mutants binding to CTX, Sym004, PNM Figure S2: Clonogenic assay in EGFR mutants with CTX, Sym004, PNM
View article: mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer Open
In patients with trastuzumab-resistant HER2-positive breast cancer, the combination of everolimus (mTORC1 inhibitor) with trastuzumab failed to show a clinically significant benefit. However, the combination of mTOR inhibition and the anti…
View article: HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer Open
Despite the clinical benefit of trastuzumab, eventually all HER2-amplified gastric cancer tumors develop drug resistance. We aimed to identify molecular mechanisms of acquired resistance to trastuzumab in gastric cancer by using well-estab…
View article: Chromium disrupts chromatin organization and CTCF access to its cognate sites in promoters of differentially expressed genes
Chromium disrupts chromatin organization and CTCF access to its cognate sites in promoters of differentially expressed genes Open
Hexavalent chromium compounds are well-established respiratory carcinogens used in industrial processes. While inhalation exposure constitutes an occupational risk affecting mostly chromium workers, environmental exposure from drinking wat…
View article: Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses Open
clinicaltrialsregister.eu Identifier: 2013-003829-29.
View article: SRC-S6 axis as a potential mechanism of resistance to anti HER2 treatment in gastric cancer (GC) cell lines
SRC-S6 axis as a potential mechanism of resistance to anti HER2 treatment in gastric cancer (GC) cell lines Open
View article: Prenatal and early postnatal lead exposure in mice: neuroimaging findings.
Prenatal and early postnatal lead exposure in mice: neuroimaging findings. Open
These data suggest that low-level, gestational lead exposure in a mouse model produces minimal changes observed by MRI.
View article: Long-term Coexposure to Hexavalent Chromium and B[<i>a</i>]P Causes Tissue-Specific Differential Biological Effects in Liver and Gastrointestinal Tract of Mice
Long-term Coexposure to Hexavalent Chromium and B[<i>a</i>]P Causes Tissue-Specific Differential Biological Effects in Liver and Gastrointestinal Tract of Mice Open
Complex mixtures of environmental agents often cause mixture-specific health effects that cannot be accounted for by a single mechanism. To study the biological effects of exposure to a mixture of chromium-VI and benzo[a]pyrene (B[a]P), of…